Go Pro
NASDAQ:AMIX

Autonomix Medical Q1 2026 Earnings Report

Autonomix Medical logo
$4.12 +0.05 (+1.11%)
As of 03:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Autonomix Medical EPS Results

Actual EPS
-$22.47
Consensus EPS
-$20.58
Beat/Miss
Missed by -$1.89
One Year Ago EPS
N/A

Autonomix Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Autonomix Medical Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Autonomix Medical's Q2 2027 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Autonomix Medical Earnings Headlines

AMIX Share News Today
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
Autonomix Medical (NASDAQ:AMIX) Stock Rating Lowered by Wall Street Zen
See More Autonomix Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Autonomix Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Autonomix Medical and other key companies, straight to your email.

About Autonomix Medical

Autonomix Medical (NASDAQ:AMIX) is a medical device company developing catheter-based technologies intended to diagnose and treat conditions involving the peripheral nervous system. The company’s platform uses a miniature sensing chip integrated into a catheter to detect and measure nerve signals in targeted areas of the body.

Autonomix is initially focused on applications in pain management, including the detection and treatment of nerves associated with chronic and cancer-related pain. Its technology is designed to help physicians identify relevant nerves more precisely and guide procedures such as targeted nerve ablation or other therapeutic interventions.

The company’s development programs remain subject to clinical testing, regulatory review and authorization before any products can be broadly commercialized. Autonomix Medical is headquartered in the United States and focuses primarily on developing its platform for use by physicians and healthcare providers.

View Autonomix Medical Profile